Antisynthetase Syndrome
Conditions
Keywords
cancer, idiopathic inflammatory myopathies
Brief summary
Among Idiopathic inflammatory myopathies, antisynthetase syndrome is meant to be rarely associated with cancer. However, clinical evidences of the association of those diseases led to the hypothesis that previous studies might have underestimated the prevalence of cancer in patients with antisynthetase syndrome. The aim of this study was to assess the prevalence of cancer in patients with antisynthetases syndrome in Grand Est and Bourgogne Franche-Comté regions.
Detailed description
Idiopathic inflammatory myopathies area heterogeneous group of disease involving mainly muscles, which paraneoplastic feature has been well characterized, specifically in some subgroups such as dermatomyositis. In contrast, antisynthetase syndrome is thought to be rarely associated with cancer. However, clinical observations of the association of those diseases led us to the hypothesis that previous studies might have underestimated the prevalence of cancer in patients with antisynthetase syndrome. The aim of this study was to assess the prevalence of cancer in patients with antisynthetases syndrome in Grand Est and Bourgogne Franche-Comté regions, describing the type of cancer observed as well as clinical features of patients and diagnostic work-up leading to the diagnosis of cancer.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire Dijon
CHU de Reims
University Hospital, Strasbourg, France
Hopitaux Prives de Metz, Groupe UNEOS
Centre Hospitalier Universitaire de Besancon
Central Hospital, Nancy, France
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* adult patients * positive antisynthetase antibodies (JO-1,PL12, PL17, EJ, OJ, KS, RS, YRS)
Exclusion criteria
* age under 18 * opposition to data collection * no positive antisynthetase antibodies * absence of clinical involvment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cancer prevalence | baseline | prevalence of cancer among patients with antisynthetase syndrome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| description of cancer type in patients with antisynthetase syndrome | baseline | description of the type and stage of cancer in patients with antisynthetase syndrome |
| factors associated with cancer | baseline | comparison of clinical and paraclinical features associated with cancer in patients with antisynthetase syndrome |
Countries
France
Contacts
Primary ContactThomas Moulinet, MD
Outcome results
None listed